Preclinical and clinical development of kinase inhibitors in acute myeloid leukemia

Preclinical and clinical development of kinase inhibitors in acute myeloid leukemia

Bibliographic Details
Main Author:	Jeon, Jae Yoon
Language:	English
Published:	The Ohio State University / OhioLINK 2020
Subjects:	Oncology Pharmacy Sciences acute myeloid leukemia FLT3 kinase inhibitors drug resistance
Online Access:	http://rave.ohiolink.edu/etdc/view?acc_num=osu158699311567933

Similar Items

Clinical use of FLT3 inhibitors in acute myeloid leukemia
by: Sutamtewagul G, et al.
Published: (2018-10-01)

FLT3 inhibitors in acute myeloid leukemia
by: Mei Wu, et al.
Published: (2018-12-01)

Targeting Oncogenic Signaling in Mutant FLT3 Acute Myeloid Leukemia: The Path to Least Resistance
by: Dilana Staudt, et al.
Published: (2018-10-01)

Targeting FLT3 Signaling in Childhood Acute Myeloid Leukemia
by: Amy N. Sexauer, et al.
Published: (2017-11-01)

The Ups and Downs of STAT Inhibition in Acute Myeloid Leukemia
by: Bernhard Moser, et al.
Published: (2021-08-01)

Preclinical efficacy for a novel tyrosine kinase inhibitor, ArQule 531 against acute myeloid leukemia
by: Ola A. Elgamal, et al.
Published: (2020-01-01)

Protein kinase inhibitors for acute leukemia
by: Yuan Ling, et al.
Published: (2018-02-01)

FLT3 Mutations in Acute Myeloid Leukemia: Key Concepts and Emerging Controversies
by: Vanessa E. Kennedy, et al.
Published: (2020-12-01)

Molecular Mechanisms of Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia: Ongoing Challenges and Future Treatments
by: Sebastian Scholl, et al.
Published: (2020-11-01)

Gold nanoparticles enhance the effect of tyrosine kinase inhibitors in acute myeloid leukemia therapy
by: Petrushev B, et al.
Published: (2016-02-01)

Midostaurin In Acute Myeloid Leukemia: An Evidence-Based Review And Patient Selection
by: Abbas HA, et al.
Published: (2019-10-01)

Mutations within the Activation Loop Domain of FLT3 in Two Pediatric Patients with Refractory Infant Acute Myeloid Leukemia
by: Nicole Muhlbauer, et al.
Published: (2020-03-01)

Mechanisms Underlying Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia
by: Motoki Eguchi, et al.
Published: (2020-07-01)

FLT3 Gene Mutation in Acute Myeloid Leukemia: Correlation with Hematological, Immunophenotypic, and Cytogenetic Characteristics
by: Sunitha Shankaralingappa, et al.
Published: (2021-06-01)

Molecular Diagnosis of FLT3 Mutations in Acute Myeloid Leukemia Patients
by: EK Zaikova, et al.
Published: (2019-03-01)

Combating drug resistance in acute myeloid leukaemia by drug rotations: the effects of quizartinib and pexidartinib
by: Jingmei Yang, et al.
Published: (2021-04-01)

Targeting Tyrosine Kinases in Acute Myeloid Leukemia: Why, Who and How?
by: Solène Fernandez, et al.
Published: (2019-07-01)

Clinical Benefits and Safety of FMS-Like Tyrosine Kinase 3 Inhibitors in Various Treatment Stages of Acute Myeloid Leukemia: A Systematic Review, Meta-Analysis, and Network Meta-Analysis
by: Qingyu Xu, et al.
Published: (2021-06-01)

An overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatment
by: Tiziana Grafone, et al.
Published: (2012-04-01)

Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia
by: Juanjuan Zhao, et al.
Published: (2019-09-01)

Autophagy activation mediates resistance to FLT3 inhibitors in acute myeloid leukemia with FLT3-ITD mutation
by: Chen, Y., et al.
Published: (2022)

The Combined Treatment With the FLT3-Inhibitor AC220 and the Complex I Inhibitor IACS-010759 Synergistically Depletes Wt- and FLT3-Mutated Acute Myeloid Leukemia Cells
by: Xiyuan Lu, et al.
Published: (2021-08-01)

Chimeric antigen receptor (CAR)-modified T cells targeting FLT3 in acute myeloid leukemia (AML)
by: Jetani, Hardikkumar
Published: (2021)

Real-World Outcomes of Patients with Refractory or Relapsed <i>FLT3</i>-ITD Acute Myeloid Leukemia: A Toulouse-Bordeaux DATAML Registry Study
by: Pierre-Yves Dumas, et al.
Published: (2020-07-01)

Clinical Implications of Inflammation in Acute Myeloid Leukemia
by: Christian Récher
Published: (2021-02-01)

Acute Myeloid Leukemia Mutations: Therapeutic Implications
by: Cristina Papayannidis, et al.
Published: (2019-06-01)

Targeted therapy for medullary and extramedullary relapse of FLT3-ITD acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation
by: Takahiro Kumode, et al.
Published: (2020-01-01)

Successful treatment with ABL tyrosine kinase inhibitor for patients with acute myeloid leukemia with BCR-ABL1
by: Asako Takeuchi, et al.
Published: (2021-01-01)

A dual inhibitor overcomes drug-resistant FLT3-ITD acute myeloid leukemia
by: Peihong Wang, et al.
Published: (2021-07-01)

SU11652 Inhibits tyrosine kinase activity of FLT3 and growth of MV-4-11 cells
by: Guo Yao, et al.
Published: (2012-12-01)

RAF Kinase Inhibitor Protein in Myeloid Leukemogenesis
by: Armin Zebisch, et al.
Published: (2019-11-01)

Targeting FLT3 in acute myeloid leukemia using ligand-based chimeric antigen receptor-engineered T cells
by: Ying Wang, et al.
Published: (2018-05-01)

Use of FLT3 inhibitors in acute myeloid leukemia remission induction or salvage therapy: systematic review and meta-analysis
by: Yang M, et al.
Published: (2018-08-01)

FREQUENCY OF FMS-LIKE TYROSINE KINASE 3 KINASE DOMAIN POINT MUTATION (FLT3/TKD MUTATION) IN DIFFERENT AGE GROUPS OF ACUTE MYELOID LEUKEMIA PATIENTS.
by: Khaleeq unnisa, et al.
Published: (2014-08-01)

Tyrosine kinase inhibitor resistance in pediatric chronic myeloid leukemia: a case report
by: Mururul Aisyi, et al.
Published: (2020-10-01)

Outcome of Relapsed or Refractory <i>FLT3</i>-Mutated Acute Myeloid Leukemia Before Second-Generation FLT3 Tyrosine Kinase Inhibitors: A Toulouse–Bordeaux DATAML Registry Study
by: Sarah Bertoli, et al.
Published: (2020-03-01)

Tyrosine kinase inhibitors induced immune thrombocytopenia in chronic myeloid leukemia?
by: Avital F. Barak, et al.
Published: (2011-12-01)

FLT3-ITD Mutation and FLT3 Ligand Plasma Level Were Not Associated with One-Year Survival of Indonesian Acute Myeloid Leukemia Patients
by: Rinaldi I, et al.
Published: (2021-02-01)

FLT3 Mutation as a Significant Prognostic Marker in de novo Acute Myeloid Leukemia Patients: Incidence, Distribution and Association with Cytogenetic Findings in a Study from South India
by: Santhi Sarojam, et al.
Published: (2014-10-01)

Biomarkers of Gemtuzumab Ozogamicin Response for Acute Myeloid Leukemia Treatment
by: Laurène Fenwarth, et al.
Published: (2020-08-01)